Adaptive Biotechnologies ... (ADPT)
| Bid | 7.5 |
| Market Cap | 1.15B |
| Revenue (ttm) | 178.96M |
| Net Income (ttm) | -159.49M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -7.15 |
| Forward PE | -11.03 |
| Analyst | Buy |
| Ask | 8.7 |
| Volume | 933,188 |
| Avg. Volume (20D) | 1,978,577 |
| Open | 7.78 |
| Previous Close | 7.82 |
| Day's Range | 7.61 - 8.01 |
| 52-Week Range | 2.28 - 9.01 |
| Beta | 1.73 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a cli...
Analyst Forecast
According to 5 analyst ratings, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 16.57% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call TranscriptAdaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Fou...
